Study links Celebrex, heart valve calcification after earlier research declared drug safe

A well-known, four-year study found popular arthritis drug Celebrex no more dangerous for the heart than older drugs in its same classification - commonly called NSAIDs. Now, a big-data analysis of patient records at Vanderbilt University has found a link specifically between Celebrex and heart valve calcification.

W. David Merryman, professor of biomedical engineering, and Ph.D. student Megan Bowler started out by testing celecoxib, the active compound in Celebrex, on valve cells in an effort to see if it could double as an aortic stenosis therapy. It made the problem worse.

To confirm their theory about a link between celecoxib and valve calcification, Merryman, who is also a professor of pharmacology, medicine and pediatrics at Vanderbilt, recruited Michael Raddatz, an M.D./Ph.D. student, to analyze more than 8,600 relevant, anonymous patient records from Vanderbilt University Medical Center. Raddatz checked whether there was a link between Celebrex use and aortic valve disease, and, after correcting for other risk factors, discovered that patients who had taken Celebrex had a 20 percent increased prevalence of valve disease.

The team's results appear today, which is National Heart Valve Disease Awareness Day, in the Journal of the American College of Cardiology (JACC): Basic to Translational Science.

The 2016 New England Journal of Medicine study that found Celebrex no more damaging than naproxen and ibuprofen only looked at cardiovascular death and nonfatal heart attack or stroke, not valve disease, which affects more than a quarter of the U.S. population older than 65.

"In this study, we're adding a long-term perspective on celecoxib use," said Bowler, who recently earned her Ph.D. "Calcification in the aortic valve can take many years. So if you're at a higher risk for it, you might want to consider taking a different painkiller or rheumatoid arthritis treatment."

As part of the same study, Bowler and Merryman found dimethyl celecoxib - an inactive form of celecoxib - could potentially slow or stop aortic stenosis. Merryman said he intends to keep testing dimethyl celecoxib for its beneficial effects on heart valve health.

Meghan A Bowler, Michael A Raddatz, Camryn L Johnson, Brian R Lindman, W David Merryman.
Celecoxib Is Associated With Dystrophic Calcification and Aortic Valve Stenosis.
JACC: Basic to Translational Science Feb 2019, 285; DOI: 10.1016/j.jacbts.2018.12.003.

Most Popular Now

Bayer Thrombosis Research Award 2019 goes to Dr. C…

The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 priz...

Roche enters into definitive merger agreement to a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeuti...

Brilinta’s Phase III THEMIS trial met primary endp…

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant red...

Jury upholds Amgen's patents on Repatha® (evolocum…

Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These pat...

Protein content as a marker for response to therap…

Brain tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for t...

Artificial lung cancer tissue could help find new …

A 3D hydrogel created by researchers in U of T Engineering Professor Molly Shoichet's lab is helping University of Ottawa researchers to quickly screen hundreds of potent...

Could medical marijuana help grandma and grandpa w…

Medical marijuana may bring relief to older people who have symptoms like pain, sleep disorders or anxiety due to chronic conditions including amyotrophic lateral scleros...

New treatment offers potentially promising results…

A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Pa...

Amgen, Cytokinetics and Servier announce start of …

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecar...

Could blockchain ensure integrity of clinical tria…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable au...

Novartis data confirm rapid response and high effi…

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosenty...

Abbott and Novo Nordisk enter partnership to provi…

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly...